Plexxikon and Wyeth Form Collaboration for PPAR Modulators
Business Review Editor
Abstract
Plexxikon has formed a multiproduct collaboration on the development Plexxikon’s PLX204 and other PPAR modulators with Wyeth Pharmaceuticals for treatments for diabetes and other metabolic disorders. The deal could worth up to US$372 M.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.